Literature DB >> 17168162

Saccadic adaptation in Chiari type II malformation.

Michael S Salman1, James A Sharpe, Moshe Eizenman, Linda Lillakas, Teresa To, Carol Westall, Martin J Steinbach, Maureen Dennis.   

Abstract

BACKGROUND: Saccadic adaptation corrects errors in saccadic amplitude. Experimentally-induced saccadic adaptation provides a method for studying motor learning. The cerebellum is a major participant in saccadic adaptation. Chiari type II malformation (CII) is a developmental deformity of the cerebellum and brainstem that is associated with spina bifida. We investigated the effects of CII on saccadic adaptation.
METHOD: We measured eye movements using an infrared eye tracker in 21 subjects with CII (CII group) and 39 typically developing children (control group), aged 8-19 years. Saccadic adaptation was induced experimentally using targets that stepped horizontally 120 to the right and then stepped backward 3 degrees during saccades.
RESULTS: Saccadic adaptation was achieved at the end of the adaptation phase in participants in each group. Saccadic amplitude gain decreased by 6.9% in the CII group and 9.3% in the control group. The groups did not differ significantly (p = 0.27). Amplitude gain reduction was significantly less in the CII participants who had multiple shunt revisions. Regression analyses revealed no effects of spinal lesion level, presence of nystagmus, or cerebellar vermis dysmorphology on saccadic adaptation.
CONCLUSION: The neural circuits involved in saccadic adaptation appear to be functionally intact in CII.

Entities:  

Mesh:

Year:  2006        PMID: 17168162     DOI: 10.1017/s0317167100005321

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  11 in total

1.  Adaptation of naturally paced saccades.

Authors:  Michael J Gray; Annabelle Blangero; James P Herman; Josh Wallman; Mark R Harwood
Journal:  J Neurophysiol       Date:  2014-03-12       Impact factor: 2.714

Review 2.  Cerebellar motor function in spina bifida meningomyelocele.

Authors:  Maureen Dennis; Michael S Salman; Jenifer Juranek; Jack M Fletcher
Journal:  Cerebellum       Date:  2010-12       Impact factor: 3.847

Review 3.  Anomalous development of brain structure and function in spina bifida myelomeningocele.

Authors:  Jenifer Juranek; Michael S Salman
Journal:  Dev Disabil Res Rev       Date:  2010

Review 4.  The cognitive phenotype of spina bifida meningomyelocele.

Authors:  Maureen Dennis; Marcia A Barnes
Journal:  Dev Disabil Res Rev       Date:  2010

5.  The cerebellar dysplasia of Chiari II malformation as revealed by eye movements.

Authors:  Michael S Salman; Maureen Dennis; James A Sharpe
Journal:  Can J Neurol Sci       Date:  2009-11       Impact factor: 2.104

6.  Verb generation in children with spina bifida.

Authors:  Maureen Dennis; Derryn Jewell; Ross Hetherington; Christine Burton; Michael E Brandt; Susan E Blaser; Jack M Fletcher
Journal:  J Int Neuropsychol Soc       Date:  2008-03       Impact factor: 2.892

7.  Visual fixation in Chiari type II malformation.

Authors:  Michael S Salman; James A Sharpe; Linda Lillakas; Maureen Dennis; Martin J Steinbach
Journal:  J Child Neurol       Date:  2009-02       Impact factor: 1.987

Review 8.  Puppets, robots, critics, and actors within a taxonomy of attention for developmental disorders.

Authors:  Maureen Dennis; Katia J Sinopoli; Jack M Fletcher; Russell Schachar
Journal:  J Int Neuropsychol Soc       Date:  2008-09       Impact factor: 2.892

9.  Perception of strong-meter and weak-meter rhythms in children with spina bifida meningomyelocele.

Authors:  Talar Hopyan; E Glenn Schellenberg; Maureen Dennis
Journal:  J Int Neuropsychol Soc       Date:  2009-07       Impact factor: 2.892

Review 10.  Why IQ is not a covariate in cognitive studies of neurodevelopmental disorders.

Authors:  Maureen Dennis; David J Francis; Paul T Cirino; Russell Schachar; Marcia A Barnes; Jack M Fletcher
Journal:  J Int Neuropsychol Soc       Date:  2009-05       Impact factor: 2.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.